Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...